Bone metastases can cause pain in patients with cancer, and 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting evaluated treating this pain.
Bone metastases can cause pain in patients with cancer, and 2 abstracts presented at the 2019 American Society of Clinical Oncology Annual Meeting evaluated treating this pain.
In the first study, the researchers analyzed the efficacy of using the OsteoCool Radiofrequency Ablation (RFA) system to treat patients with painful bone metastases.1
A total of 37 patients at 8 US centers were enrolled between October 2017 and August 2018 and underwent RFA. The patients had no more than 2 painful target sites involving the thoracolumbar spine, pelvis, and/or sacrum. The worst pain was measured at ≥4/10 by the Brief Pain Inventory (BPI).
The patients were evaluated prior to RFA, at discharge, and then 3 days, 1 week, and 1, 3, 6, and 12 months after discharge. At baseline, the mean worst pain measured by BPI was 8.6. The most common primary cancers among the patients were breast (32%) and lung (24%).
At 1 week after treatment, 74% (25/34) of patients presenting at the visit reported a clinically significant change of ≥2 points in worst pain from baseline. Of the 14 patients presenting at the 3-month visit, 13 (93%) reported a clinically significant change. The same proportion of patients at the 3-month visit did not undergo radiation therapy at the targeted site(s) between baseline and the 3-month visit.
There were 11 deaths, but they were all attributed to the underlying cancer and were deemed not to be related to the RFA treatment.
“The preliminary results of the OPuS One study show rapid pain improvement at 1 week and sustained long-term relief through 3 months in patients with metastatic bone disease,” the authors concluded.
The second study analyzed the use of single-fraction radiotherapy (SFRT) in Australia.2 It included 10,351 patients who had received a total of 15,668 courses of radiotherapy for bone metastases.
Overall, SFRT accounted for 18% of the courses. Evaluating the use of SFRT over time showed that there had been no significant change, with SFRT accounting for 18% in 2012, as well. In 2017, it accounted for 20% of radiotherapy courses.
The researchers found that older patients were more likely to have SFRT versus multifraction radiotherapy (MFRT), as well as patients who had lung cancer and prostate cancer. Patients in major cities were less likely to receive SFRT, as were patients being treated for metastases on the spine. Private institutions were also less likely to treat with SFRT compared with public institutions.
“There is large variation in SFRT use depending on patient, tumour, geographical, and institutional factors,” the authors concluded. “Further work is needed to increase uptake, and reduce unwarranted variation, in SFRT use.”
References
1. Bagla S, Levy J, Hopkins T, OPuS One Study Investigators. Effect on pain outcomes in patients treated for painful bone metastases with bipolar RFA: The OPuS One study. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, IL. Abstract: 11605.
2. Ong WL, Foroudi F, Millar JL. Australian population-based study of single- versus multi-fraction palliative radiotherapy for bone metastases. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, IL. Abstract: 6568.
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More
Combining Surgical, Nonsurgical Approaches Holds Promise for Treating Facial Acne Scars
May 4th 2024According to a review, recent progress offers hope in the form of treatments, such as combination therapy that utilizes surgical and nonsurgical methods, for individuals with facial acne scars.
Read More